Lbp Am Sa Decreases Stake in Merck & Co., Inc. (NYSE:MRK)

Lbp Am Sa lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 7.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 368,787 shares of the company’s stock after selling 30,365 shares during the quarter. Lbp Am Sa’s holdings in Merck & Co., Inc. were worth $36,687,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Tradewinds LLC. grew its holdings in Merck & Co., Inc. by 0.6% during the third quarter. Tradewinds LLC. now owns 15,649 shares of the company’s stock worth $1,777,000 after acquiring an additional 101 shares during the period. CGN Advisors LLC grew its holdings in Merck & Co., Inc. by 0.4% during the fourth quarter. CGN Advisors LLC now owns 26,969 shares of the company’s stock worth $2,683,000 after acquiring an additional 102 shares during the period. Accredited Investors Inc. grew its holdings in Merck & Co., Inc. by 0.9% during the third quarter. Accredited Investors Inc. now owns 11,834 shares of the company’s stock worth $1,344,000 after acquiring an additional 109 shares during the period. Cypress Wealth Services LLC grew its holdings in Merck & Co., Inc. by 3.1% during the fourth quarter. Cypress Wealth Services LLC now owns 3,639 shares of the company’s stock worth $362,000 after acquiring an additional 111 shares during the period. Finally, TI Trust Inc. grew its holdings in Merck & Co., Inc. by 0.6% during the fourth quarter. TI Trust Inc. now owns 19,834 shares of the company’s stock worth $1,973,000 after acquiring an additional 111 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 1.4 %

Shares of NYSE MRK opened at $94.64 on Friday. Merck & Co., Inc. has a one year low of $81.04 and a one year high of $134.63. The firm has a market capitalization of $239.07 billion, a PE ratio of 14.06, a PEG ratio of 0.77 and a beta of 0.35. The company has a current ratio of 1.36, a quick ratio of 1.15 and a debt-to-equity ratio of 0.79. The business has a 50-day moving average price of $93.66 and a two-hundred day moving average price of $102.14.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, February 4th. The company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.85 by ($0.13). The firm had revenue of $15.62 billion for the quarter, compared to analyst estimates of $15.51 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.03 earnings per share. As a group, analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. declared that its Board of Directors has authorized a share buyback plan on Tuesday, January 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 4.1% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be issued a dividend of $0.81 per share. The ex-dividend date is Monday, March 17th. This represents a $3.24 annualized dividend and a dividend yield of 3.42%. Merck & Co., Inc.’s dividend payout ratio is 48.14%.

Insider Activity

In other news, insider Cristal N. Downing sold 2,361 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $88.76, for a total transaction of $209,562.36. Following the completion of the sale, the insider now directly owns 7,085 shares in the company, valued at $628,864.60. The trade was a 24.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Inge G. Thulin purchased 2,833 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 6th. The shares were purchased at an average price of $88.25 per share, with a total value of $250,012.25. Following the completion of the acquisition, the director now owns 2,933 shares in the company, valued at $258,837.25. The trade was a 2,833.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.09% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Bank of America lowered their target price on Merck & Co., Inc. from $118.00 to $112.00 and set a “buy” rating on the stock in a report on Wednesday, February 5th. Truist Financial reaffirmed a “hold” rating and set a $110.00 target price (down from $130.00) on shares of Merck & Co., Inc. in a report on Wednesday, January 8th. Morgan Stanley lowered their target price on Merck & Co., Inc. from $113.00 to $106.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. HSBC upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $130.00 price target for the company in a research report on Wednesday, December 4th. Finally, Citigroup decreased their price target on Merck & Co., Inc. from $125.00 to $115.00 and set a “buy” rating for the company in a research report on Wednesday, February 5th. Eleven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $117.12.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.